Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vera Ehrenstein, Rohini K Hernandez, Merete Lund Maegbaek, Johnny Kahlert, Mary Nguyen-Nielsen, Mette Nørgaard & Alexander Liede. (2015) Validation of algorithms to detect distant metastases in men with prostate cancer using routine registry data in Denmark. Clinical Epidemiology 7, pages 259-265.
Read now
Read now
Johanna M. Mattsson, Pirjo Laakkonen, Ulf‐Håkan Stenman & Hannu Koistinen. (2009) Antiangiogenic properties of prostate‐specific antigen (PSA). Scandinavian Journal of Clinical and Laboratory Investigation 69:4, pages 447-451.
Read now
Read now
Articles from other publishers (47)
Kyle Dymanus, Lauren E. Howard, Taofik Oyekunle, Amanda M. De Hoedt, Artak Labadzhyan, Thomas Polascik, Stephen J. Freedland & Zachary Klaassen. (2022) Are higher pre‐diagnosis follicle stimulating hormone levels associated with long‐term prostate cancer risk?. The Prostate 82:16, pages 1558-1563.
Crossref
Crossref
Xiaonan Gao, Tianrun Niu, Qinghua Xia, Bo Hu, Zengteng Zhao, Xinyi Feng, Jingqi Yang, Bo Tang & Kehua Xu. (2022) Au–Se bonded nanoprobe for prostate specific antigen detection in serum. Analytica Chimica Acta 1210, pages 339852.
Crossref
Crossref
Susan Moradinasab, Atieh Pourbagheri-Sigaroodi, Seyed H. Ghaffari & Davood Bashash. (2022) Targeting macrophage-mediated tumor cell phagocytosis: An overview of phagocytosis checkpoints blockade, nanomedicine intervention, and engineered CAR-macrophage therapy. International Immunopharmacology 103, pages 108499.
Crossref
Crossref
Peggi M. Angel & Stephen C. Zambrzycki. 2022. Stromal Signaling in Cancer. Stromal Signaling in Cancer
15
45
.
Josephine Aidoo-Brown, Despina Moschou & Pedro Estrela. (2021) Multiplexed Prostate Cancer Companion Diagnostic Devices. Sensors 21:15, pages 5023.
Crossref
Crossref
Bernd Schöpf, Hansi Weissensteiner, Georg Schäfer, Federica Fazzini, Pornpimol Charoentong, Andreas Naschberger, Bernhard Rupp, Liane Fendt, Valesca Bukur, Irina Giese, Patrick Sorn, Ana Carolina Sant’Anna-Silva, Javier Iglesias-Gonzalez, Ugur Sahin, Florian Kronenberg, Erich Gnaiger & Helmut Klocker. (2020) OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation. Nature Communications 11:1.
Crossref
Crossref
Anna Kwiatkowska, Frédéric Couture, Samia Ait-Mohand, Roxane Desjardins, Yves L. Dory, Brigitte Guérin & Robert Day. (2019) Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug. Scientific Reports 9:1.
Crossref
Crossref
D. Nathan Kim, Christopher Straka, L. Chinsoo Cho, Yair Lotan, Jingsheng Yan, Brian Kavanagh, David Raben, Susan Cooley, Jeffrey Brindle, Xian Jin Xie, David Pistenmaa & Robert Timmerman. (2017) Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Practical Radiation Oncology 7:1, pages e43-e49.
Crossref
Crossref
Sophie M. Bruinsma, Chris H. Bangma, Peter R. Carroll, Michael S. Leapman, Antti Rannikko, Neophytos Petrides, Mahesha Weerakoon, Leonard P. Bokhorst & Monique J. Roobol. (2016) Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nature Reviews Urology 13:3, pages 151-167.
Crossref
Crossref
Massimo Lazzeri, Giorgio Guazzoni & Francesco Montorsi. 2016. Prostate Cancer. Prostate Cancer
83
90
.
Sarita Mac Cornick, Silvana Aparecida Alves Corrêa, Márcia Eli Girotti, João Paulo Zambon, Rogério Simonetti Alves & Fernando Gonçalves de Almeida. (2015) Impact of Radical Prostatectomy on Urinary Incontinence, Erectile Dysfunction and General Quality of Life. Journal of Biosciences and Medicines 03:08, pages 62-75.
Crossref
Crossref
Kleita Michaelidou, Athina Kladi-Skandali & Andreas Scorilas. 2015. Biomarkers in Cancer. Biomarkers in Cancer
135
165
.
Johanna M. Mattsson, Suvi Ravela, Can Hekim, Magnus Jonsson, Johan Malm, Ale Närvänen, Ulf-Håkan Stenman & Hannu Koistinen. (2014) Proteolytic Activity of Prostate-Specific Antigen (PSA) towards Protein Substrates and Effect of Peptides Stimulating PSA Activity. PLoS ONE 9:9, pages e107819.
Crossref
Crossref
Kristian Meinander, Miikka Pakkala, Janne Weisell, Ulf-Håkan Stenman, Hannu Koistinen, Ale Närvänen & Erik A. A. Wallén. (2013) Replacement of the Disulfide Bridge in a KLK3-Stimulating Peptide Using Orthogonally Protected Building Blocks. ACS Medicinal Chemistry Letters 5:2, pages 162-165.
Crossref
Crossref
Hannu Koistinen & Ulf-Håkan StenmanHannu KoistinenUlf-Håkan Stenman. 2014. Novel Approaches in Immunoassays. Novel Approaches in Immunoassays
42
51
.
Stephen A. Gudas. 2014. A Comprehensive Guide to Geriatric Rehabilitation. A Comprehensive Guide to Geriatric Rehabilitation
261
264
.
Kleita Michaelidou, Athina Kladi-Skandali & Andreas Scorilas. 2014. Biomarkers in Cancer. Biomarkers in Cancer
1
25
.
Arnauld Villers, Philippe Puech, Hashim Uddin Ahmed & Mark Emberton. 2013. Prostate Cancer Diagnosis. Prostate Cancer Diagnosis
337
349
.
Arnauld Villers & Adil Ouzzane. 2013. Imaging and Focal Therapy of Early Prostate Cancer. Imaging and Focal Therapy of Early Prostate Cancer
133
140
.
Diederick Duijvesz & Guido Jenster. 2013. Prostate Cancer: A Comprehensive Perspective. Prostate Cancer: A Comprehensive Perspective
423
444
.
Lei Zhu, Sari Jäämaa, Taija M. af Hällström, Marikki Laiho, Anna Sankila, Stig Nordling, Ulf‐Håkan Stenman & Hannu Koistinen. (2012)
PSA forms complexes with α
1
‐antichymotrypsin in prostate
. The Prostate 73:2, pages 219-226.
Crossref
Crossref
Hans Van der Wall, Barry Elison, Clayton Frater, Warwick Bruce & Stephen Clarke. 2012. Radionuclide and Hybrid Bone Imaging. Radionuclide and Hybrid Bone Imaging
59
84
.
Joseph D. Khoury, Dorothy M. Adcock, Fanny Chan, James T. Symanowski, Stefan Tiefenbacher, Oscar Goodman, Lazara Paz, Yupo Ma, David C. Ward, Nicholas J. Vogelzang & Louis M. Fink. (2010) Increases in Quantitative D-Dimer Levels Correlate With Progressive Disease Better Than Circulating Tumor Cell Counts in Patients With Refractory Prostate Cancer. American Journal of Clinical Pathology 134:6, pages 964-969.
Crossref
Crossref
Chris H. Bangma, Ron H. van Schaik, Bert G. Blijenberg, Monique J. Roobol, Hans Lilja & Ulf-Håkan Stenman. (2010) On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. European Journal of Cancer 46:17, pages 3109-3119.
Crossref
Crossref
Antonio B. Porcaro, Filippo Migliorini, Mario Romano, Aldo Petrozziello, Stefano Zecchini Antoniolli, Emanuele Rubilotta, Vincenzo Lacola, Teodoro Sava, Claudio Ghimenton, Beatrice Caruso, Carmelo Monaco & Luigi Comunale. (2009) Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients. International Urology and Nephrology 42:3, pages 673-681.
Crossref
Crossref
Miikka Pakkala, Janne Weisell, Can Hekim, Jouko Vepsäläinen, Erik A. A. Wallen, Ulf-Håkan Stenman, Hannu Koistinen & Ale Närvänen. (2009) Mimetics of the disulfide bridge between the N- and C-terminal cysteines of the KLK3-stimulating peptide B-2. Amino Acids 39:1, pages 233-242.
Crossref
Crossref
Michael Giesing, Bernhard Suchy, Gerhard Driesel & Dietmar Molitor. (2010) Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate‐specific antigen levels of 4–10 ng/mL and disease prognostication after radical prostatectomy. BJU International 105:7, pages 1000-1010.
Crossref
Crossref
Cristiano S. Paiva, Cássio Andreoni, Graziella P. Cunha, Walid Khalil & Valdemar Ortiz. (2009) Differences among patients undergoing perineal or retropubic radical prostatectomy in pain and perioperative variables: a prospective study. BJU International 104:9, pages 1219-1226.
Crossref
Crossref
Vincenzo Ficarra, Giacomo Novara & Antonio Galfano. (2009) Precursor Isoform of Prostate-Specific Antigen and Human Kallikrein 2: Two New Promising Biomarkers for the Unsolved Challenge of Early Prostate Cancer Detection. European Urology 55:3, pages 556-559.
Crossref
Crossref
Michael Marberger. (2009) Prostate Cancer 2008: Challenges in Diagnosis and Management. European Urology Supplements 8:3, pages 89-96.
Crossref
Crossref
Fritz H. Schröder. 2009. Cancer Prevention II. Cancer Prevention II
173
182
.
Shannon Reagan‐Shaw, Minakshi Nihal, Haseeb Ahsan, Hasan Mukhtar & Nihal Ahmad. (2008) Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl‐2 ratio. The Prostate 68:15, pages 1624-1634.
Crossref
Crossref
Patrik Finne, Anssi Auvinen, Liisa Määttänen, Teuvo L. Tammela, Mirja Ruutu, Harri Juusela, Paula Martikainen, Matti Hakama & Ulf-Håkan Stenman. (2008) Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of <3.0μg per Liter. European Urology 54:2, pages 362-370.
Crossref
Crossref
Hannu Koistinen, Ale Närvänen, Miikka Pakkala, Can Hekim, Johanna M. Mattsson, Lei Zhu, Pirjo Laakkonen & Ulf-Håkan Stenman. (2008) Development of peptides specifically modulating the activity of KLK2 and KLK3. bchm 389:6, pages 633-642.
Crossref
Crossref
Jan-Erik Damber & Gunnar Aus. (2008) Prostate cancer. The Lancet 371:9625, pages 1710-1721.
Crossref
Crossref
Denise R. Aberle & Kathleen Brown. (2008) Lung Cancer Screening with CT. Clinics in Chest Medicine 29:1, pages 1-14.
Crossref
Crossref
P. Irigaray, J.A. Newby, R. Clapp, L. Hardell, V. Howard, L. Montagnier, S. Epstein & D. Belpomme. (2007) Lifestyle-related factors and environmental agents causing cancer: An overview. Biomedicine & Pharmacotherapy 61:10, pages 640-658.
Crossref
Crossref
J.A. Newby, C.C. Busby, C.V. Howard & M.J. Platt. (2007) The cancer incidence temporality index: An index to show temporal changes in the age of onset of overall and specific cancer (England and Wales, 1971–1999). Biomedicine & Pharmacotherapy 61:10, pages 623-630.
Crossref
Crossref
Meng Qiao & Arthur B. Pardee. (2007) Biomarkers, regerons, and pathways to lethal cancer. Journal of Cellular Biochemistry 102:5, pages 1076-1086.
Crossref
Crossref
J Bucerius, H Ahmadzadehfar, N Hortling, A Y Joe, H Palmedo & H-J Biersack. (2007) Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer. Prostate Cancer and Prostatic Diseases 10:3, pages 307-310.
Crossref
Crossref
Jiri Heracek, Hampl Richard, Hill Martin, Starka Luboslav, Sachova Jana, Kuncova Jitka, Eis Vaclav, Urban Michael & Mandys Vaclav. (2007) Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72:4, pages 375-380.
Crossref
Crossref
Hans Lilja, Andrew Vickers & Peter Scardino. (2007) Measurements of Proteases or Protease System Components in Blood to Enhance Prediction of Disease Risk or Outcome in Possible Cancer. Journal of Clinical Oncology 25:4, pages 347-348.
Crossref
Crossref
Stephen A. Gudas. 2007. Geriatric Rehabilitation Manual. Geriatric Rehabilitation Manual
245
247
.
F.H. Schröder. (2006) Biomarkers and screening for prostate cancer. Annals of Oncology 17, pages x200-x206.
Crossref
Crossref
Carsten Stephan, Hellmuth-Alexander Meyer, Henning Cammann, Terukazu Nakamura, Eleftherios P. Diamandis & Klaus Jung. (2006) Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biological Chemistry 387:6, pages 801-805.
Crossref
Crossref
Can Hekim, Jari Leinonen, Ale Närvänen, Hannu Koistinen, Lei Zhu, Erkki Koivunen, Ville Väisänen & Ulf-Håkan Stenman. (2006) Novel Peptide Inhibitors of Human Kallikrein 2. Journal of Biological Chemistry 281:18, pages 12555-12560.
Crossref
Crossref
Ulf-Håkan Stenman. (2006) Re: Prostate Specific Antigen Levels in Young Adulthood Predict Prostate Cancer Risk: Results from a Cohort of Black and White Americans. European Urology 49:5, pages 925.
Crossref
Crossref